Dados do Trabalho

Título

REAL-WORLD EVIDENCE OF TOLERANCE AND EFFICACIOUS OF FLOT-4 PERIOPERATIVE CHEMOTHERAPY REGIMEN FOR GASTRIC CANCER PATIENTS: A SINGLE CENTER PUBLIC HEALTH SYSTEM EXPERIENCE

Introdução

The FLOT-4 (fluorouracil, leucovorin, oxaliplatin and docetaxel) perioperative chemotherapy regimen is consider a standard of care for localized or locally advanced gastric adenocarcinoma (GC) or gastroesophageal junction (GEJ) adenocarcinoma.

Objetivo

Evaluate real-world data and external validation of FLOT-4 regimen focusing on safety and efficacious endpoints

Método

This is a collaborative retrospective study of two university hospitals that attend the brazilian public health system. Eligible criterias included patients (pts) initially diagnosed with localized, locally advanced or oligometastatic GC or GEJ adenocarcinomas that received after tumor board discussion FLOT-4 perioperative chemotherapy by at least one cycle between january 2019 and december 2020. All data was collected by electronic medical charts.

Resultado

We included a total of 23 pts in this analysis. The median age was 56 years old, being 52% of male (n=12). The main symptom reported was loss of weight (n=11 ; 52%) and the median body mass index was 24 kg/m2. A slight more than a half (n=13 ; 56%) of pts had signet ring cell histological subtype, about two of three pts included (n=16 ; 69%) had locally advanced disease and only 25% of pts underwent laparoscopic staging. Regarding FLOT-4 tolerance, 52% (n=12) pts reported adverse effects and 21,7% (n=5) had serious adverse events or needed dose reduction. A total of 10 (43,5%) pts underwent curative surgery after four cycles of preoperative FLOT-4 regimen and, of note, all of them received the next four post operative cycles. We did not find any complete pathological response and most of the pts had ypT1 (n=3) ypT3 (n=3) and ypN0 (n=6) diseases. During this short follow-up period, the recurrent-free survival rate in one and two-years were 70,8% and 53%, respectively.

Conclusão

The FLOT-4 regimen appears to be a feasible in the brazilian public health system, with potential comparabible survival rates and tolerance to the literature. We hope to this study can colaborate to the limited data in order to improve GC and GEJ cancer care.

Palavras-chave

Gastric Cancer - Chemotherapy - Gastrectomy